Study of Adaptive Radiotherapy for High-grade Glioma Based on Interfraction MRI
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: adaptive radiotherapy.
- Who it may be relevant to
- Registry conditions: High-grade Glioma. Basic parameters: 18 years — 70 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Study of Adaptive Radiotherapy for High-grade Glioma Based on Interfraction Magnetic Resonance Imaging (MRI)
Overview
The changes of target and organs at risk in patients with high-grade glioma during concurrent chemoradiotherapy were evaluated by MRI image between radiotherapy fractions.
Detailed description
To prospectively evaluate the changes of target organs and risk organs in patients with high-grade glioma during concurrent chemoradiotherapy.The related factors causing this change are discussed.The relationship between changes and patient survival was analyzed.A predictive model was established to provide individualized adaptive radiotherapy for patients.
Interventions
- Device adaptive radiotherapy
MRI was performed and adaptive radiotherapy was administered at farction10 and fraction 20 during radiotherapy.
Primary outcome measures
- Homogeneity index [Time frame: up to 2 weeks]
- conformity index [Time frame: up to 2 weeks]
- Anatomic change [Time frame: up to 2 weeks]
Secondary outcome measures (1)
- progression-free survival (PFS) [Time frame: assessed up to 12 months]
Eligibility criteria
Inclusion criteria
- Age ≥18 years old;
- High-grade glioma was confirmed by pathology after surgery;
- ECOG score 0-2 points;
- Receiving the standard STUPP regimen (i.e. 6 weeks of temozolomide concurrent chemoradiotherapy +6 cycles of temozolomide adjuvant chemotherapy);
- Baseline data available.
Exclusion criteria
- The pathological diagnosis is not clear;
- No synchronous chemotherapy/adjuvant chemotherapy \< 6 cycles;
- There are other malignant tumors;
- Previously radiotherapy to the head;
- Interruption of radiotherapy for more than 5 days;
- Failure to collect baseline data.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- West China Hospital — Chengdu
Identifiers
NCT: NCT06201351 · Trial No. 1460, 2023